Phase II Open Label Study of Anakinra in Intravenous Immunoglobulin–Resistant Kawasaki Disease

• Published in: Arthritis & rheumatology (Hoboken, N.J.) N.J.), 2021-01, Vol.73 (1), p.151-161
• Main Authors: Koné‐Paut, Isabelle, Tellier, Stéphanie, Belot, Alexandre, Brochard, Karine, Guitton, Corinne, Marie, Isabelle, Meinzer, Ulrich, Cherqaoui, Bilade, Galeotti, Caroline, Boukhedouni, Nadja, Agostini, Helene, Arditi, Moshe, Lambert, Virginie, Piedvache, Céline
• Format: Article
• Language: English
• Subjects: Animal models; Antirheumatic Agents - therapeutic use; Body temperature; C-Reactive Protein - immunology; Child; Child, Preschool; Confidence intervals; Coronary Aneurysm - diagnostic imaging; Coronary artery; Coronary vessels; Echocardiography; Evaluation; Female; Fever; Humans; Immunoglobulins; Immunoglobulins, Intravenous - therapeutic use; Immunologic Factors - therapeutic use; Infant; Interleukin 1 receptor antagonist; Interleukin 1 Receptor Antagonist Protein - therapeutic use; Interleukins; Intravenous administration; Kawasaki disease; Life Sciences; Male; Mucocutaneous lymph node syndrome; Mucocutaneous Lymph Node Syndrome - diagnostic imaging; Mucocutaneous Lymph Node Syndrome - drug therapy; Mucocutaneous Lymph Node Syndrome - immunology; Mucocutaneous Lymph Node Syndrome - physiopathology; Proof of Concept Study; Steroids; Treatment Failure; Treatment Outcome; Veins & arteries
• ISSN: 2326-5191; 2326-5205; 2326-5205; 2326-5191
• DOI: 10.1002/art.41481

Objective Anakinra has been shown to be successful in preventing and treating cardiovascular lesions both in experimental murine models of Kawasaki disease (KD) and in several studies on intravenous immunoglobulin (IVIG)– and steroid‐resistant patients with KD. This study was undertaken to determine the safety of blocking interleukin‐1 in patients with IVIG‐resistant KD. Methods Sixteen patients were included in the present study. Patients with KD who were not responsive to 1 or more courses of 2 mg/kg of IVIG received anakinra by subcutaneous daily injections. Starting doses were 2 mg/kg of IVIG (4 mg/kg in patients who were age 38°C, indicative of a fever. Treatment duration was 14 days. The last visit was on day 45. Primary outcome was abatement of fever. Secondary measures included disease activity, coronary artery Z score, and C‐reactive protein (CRP) levels. Results Seventy‐five percent of patients in the intention‐to‐treat group and 87.5% in the per‐protocol group became afebrile within 48 hours of the last escalation dose of anakinra. Reduction of disease activity by 50% was indicated on 93.3% (95% confidence interval [95% CI] 68.1–99.8%) of physician evaluations and on 100% (95% CI 73.5–100%) of parent evaluations. CRP values normalized by day 30. At the initial screening, 12 of 16 patients had a maximum coronary artery Z score of >2, and 10 of 16 patients had a maximum Z score of >2.5. At day 45, 5 of 10 patients (50% [95% CI 18.7–81.3%]) and 6 of 12 patients (50% [95% CI 21.1–78.9%]) had achieved coronary artery Z scores of